Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 03/07/2019 |
| Rapid review completed | 19/07/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care. |